mk-2206
Advanced Adult Hepatocellular Carcinoma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Advanced Adult Hepatocellular Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Roswell Park Cancer Institute | Phase 3 | BBB |
Ethiodized Oil Shenzhen SiBiono GeneTech Co.,Ltd | Phase 2 | B |
Epirubicin Roswell Park Cancer Institute | Phase 1/2 | B |
Theprubicin Shenzhen SiBiono GeneTech Co.,Ltd | Phase 2 | B |
Allovax Mirror Biologics, Inc. | Phase 2 | B |
View all 18 →
Same molecule, other indications
mk-2206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →